熱門資訊> 正文
VolutionRx报告财年业绩
2026-04-01 18:33
- VolitionRX press release (VNRX): FY Revenue of $1.7M, representing growth of 40% over the previous year..
- Net loss was down 14% for the year versus 2024.
- Net cash used in operating activities was $19.7 million for the year, down 24%.
More on VolitionRX
- VolitionRx Limited secures €2M non-dilutive funding from Belgian agencies
- VolitionRx receives NYSE non-compliance notice
- Seeking Alpha’s Quant Rating on VolitionRX
- Historical earnings data for VolitionRX
- Financial information for VolitionRX
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
